Merck 2010 Annual Report Download - page 148

Within the scope of the following overview of the purchase price allocation in accordance with
IFRS 3, the acquired assets, liabilities and contingent liabilities have been recognized at fair values
in the balance sheet:
EUR million
Fair value on the
acquisition date

Cash and cash equivalents, marketable securities and other financial assets 300.0
Inventories 265.5
Receivables 257.0
Other current assets 13.8


Goodwill 2,704.4
Other intangible assets 2,559.5
Property, plant and equipment 474.2
Investments at equity 2.2
Other non-current assets 3.2
Deferred tax assets 96.3

 

Current financial liabilities 574.8
Other current liabilities 341.7


Non-current financial liabilities 288.4
Provisions for pensions and other post-employment benefits 54.9
Other non-current liabilities 20.3
Deferred tax liabilities 790.2

 
 
 
 
 
 
The most significant impact of the purchase price allocation on the balance sheet and the income
statement results from the fair value adjustment of intangible assets and inventories. The adjust-
ments to intangible assets relate mainly to the measurement of the existing customer relationships,
technologies, trademarks and brands as well as ongoing development projects. The amortization of
intangible assets resulting from the acquisition of Millipore is disclosed in the income statement
under “Amortization of intangible assets”. Additionally, fair value adjustments totaling EUR 85.8 mil-
lion were made in respect of Millipore inventories acquired as part of the acquisition. The complete
144 Merck Annual Report 2010